ReviewJournal of the advanced practitioner in oncology2014
Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma.
Review in Journal of the advanced practitioner in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Review of the Neurosurgical Management of Brain Metastases During Pregnancy.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2021Pooled it
- Unraveling Skin Carcinoma: A Comprehensive Examination of Diagnosis, Treatment Strategies, and Emerging Therapeutic Avenues in Skin Cancer Management.Pharmaceutical nanotechnology · 2025Review
- Design, Virtual Screening, Molecular Docking, ADME and Cytotoxicity Studies of 1,3,5-Triazine Containing Heterocyclic Scaffolds as Selective BRAF Monomeric, Homo and Heterodimeric Inhibitors.Combinatorial chemistry & high throughput screening · 2025Article
- Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.NPJ systems biology and applications · 2024Article
- Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.British journal of cancer · 2021Article
- Personalized treatment options for thyroid cancer: current perspectives.Pharmacogenomics and personalized medicine · 2019Review
- Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.Molecular cancer · 2018Review
- Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.International journal of molecular sciences · 2017Review
- Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma.Scientific reports · 2016Article
- Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death.International journal of oncology · 2015Article
- Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.Molecular and cellular biochemistry · 2015Article
- Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells.Biomolecules & therapeutics · 2015Article
- Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells.Cellular signalling · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
25089220PMC4114496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.